- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00004868
SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation Therapy
A Phase I/II Trial of SU5416 in Patients With Recurrent High Grade Astrocytomas or Mixed Gliomas
RATIONALE: SU5416 may stop the growth of astrocytoma or glioma by stopping blood flow to the tumor.
PURPOSE: Phase I/II trial to study the effectiveness of SU5416 in treating patients who have recurrent astrocytoma or mixed glioma that has not responded to previous radiation therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES: Phase I:
- Determine the maximum tolerated dose of SU5416 in patients with recurrent malignant glioma who are, as well as those who are not, taking enzyme-inducing antiepileptic drugs.
- Determine the toxic effects (safety profile) of this drug in this patient population.
- Characterize the pharmacokinetics of this drug in these patients.
- Develop exploratory data relative to surrogate endpoints of angiogenic activity in vivo, including functional imaging and in vitro assays of endothelial cell inhibition and serum angiogenic peptides.
Phase II:
- Determine the efficacy of SU5416, in terms of 6-month progression-free survival, in patients with recurrent high-grade glioma.
- Determine, further, the safety profile of the phase II dose of this drug in this patient population.
- Develop exploratory data relative to surrogate endpoints of angiogenic activity in vivo including functional imaging and in vitro assays of endothelial cell inhibition and serum angiogenic peptides.
OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to concurrent enzyme-inducing antiepileptic drugs (no vs yes).
Patients receive SU5416 IV on days 1 and 4 weekly for 4 weeks. Courses repeat every 4 weeks in the absence of unacceptable toxicity or disease progression.
Cohorts of 3-6 patients receive escalating doses of SU5416 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD has been determined, additional patients are accrued to the phase II portion of the study. These patients receive SU5416 IV, as in the phase I portion, at the appropriate MTD established in phase I.
Patients are followed for survival.
PROJECTED ACCRUAL: At least 30 patients will be accrued for the phase I dose-escalation portion of this study within 10 months. An additional 48 patients (32 with glioblastoma multiforme and 16 with anaplastic glioma) will be accrued for the phase II portion of this study within 6-8 months.
Study Type
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095-1781
- Jonsson Comprehensive Cancer Center, UCLA
-
San Francisco, California, United States, 94143-0128
- UCSF Cancer Center and Cancer Research Institute
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- Neuro-Oncology Branch
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-0752
- University of Michigan Comprehensive Cancer Center
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Children's Hospital of Pittsburgh
-
Pittsburgh, Pennsylvania, United States, 15213-3489
- University of Pittsburgh Cancer Institute
-
-
Texas
-
Dallas, Texas, United States, 75235-9154
- Simmons Cancer Center - Dallas
-
Houston, Texas, United States, 77030-4009
- University of Texas - MD Anderson Cancer Center
-
San Antonio, Texas, United States, 78284-7811
- University of Texas Health Science Center at San Antonio
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792-6164
- University of Wisconsin Comprehensive Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically proven supratentorial malignant primary glioma, including:
- Glioblastoma multiforme
- Anaplastic astrocytoma
- Anaplastic oligodendroglioma
- Anaplastic mixed oligoastrocytoma
- Malignant astrocytoma not otherwise specified
- Benign or malignant meningiomas, including brain and spinal meningiomas
- Patients with meningiomas are excluded from phase II portion of study
- Must have shown unequivocal evidence of tumor recurrence or progression by CT scan or MRI
- Must have failed prior radiotherapy
Must have prestudy contrast MRI or contrast CT scan of brain on stable steroid dose within the past 14 days
- Must be on stable (unchanged) dose of steroids for at least 5 days before scans
Phase II:
- Must have completed radiotherapy at least 2 months prior to enrollment
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- Karnofsky 60-100%
Life expectancy:
- More than 8 weeks
Hematopoietic:
- WBC at least 2,300/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 8 g/dL (transfusion allowed)
Hepatic:
- SGOT less than 2.5 times upper limit of normal
- Bilirubin normal
- No significant active hepatic disease
Renal:
- Creatinine less than 1.5 mg/dL OR
- Creatinine clearance at least 60 mL/min
- No significant active renal disease
Cardiovascular:
- No uncompensated coronary artery disease on ECG or physical examination
- No history of myocardial infarction or severe/unstable angina within the past 6 months
- No deep venous or arterial thrombosis within the past 3 months
Pulmonary:
- No pulmonary embolism within the past 3 months
Other:
- Not pregnant or nursing
- Fertile patients must use effective contraception during and for 2 months after study
- No other serious concurrent illness
- No significant active psychiatric disease
- No diabetes mellitus with severe peripheral vascular disease
- No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix
- No serious active infection
- No other concurrent disease that would obscure toxic effects or dangerously alter drug metabolism
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- At least 3 weeks since prior biologic therapy (e.g., interferon) and recovered
- No concurrent immunotherapy
Chemotherapy:
Phase I:
- No more than 2 prior chemotherapy regimens for recurrent disease
Phase II:
- No more than 1 prior chemotherapy regimen for recurrent disease
- At least 2 weeks since prior vincristine
- At least 6 weeks since prior nitrosoureas
- At least 3 weeks since prior procarbazine
- Recovered from prior chemotherapy
- No concurrent chemotherapy
Endocrine therapy:
- See Disease Characteristics
- At least 3 weeks since prior endocrine therapy (e.g., tamoxifen) and recovered
Radiotherapy:
- See Disease Characteristics
- No concurrent radiotherapy
Surgery:
- Recovered from prior surgery
- Recent prior resection of recurrent or progressive tumor allowed
Other:
- No other concurrent investigational agents
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Glioma
- Nervous System Neoplasms
- Central Nervous System Neoplasms
- Astrocytoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Semaxinib
Other Study ID Numbers
- NABTC-9902
- CDR0000067527 (REGISTRY: PDQ (Physician Data Query))
- MSKCC-01045
- NCI-00-C-0173
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Brain and Central Nervous System Tumors
-
Children's Hospital Los AngelesUnknownBrain and Central Nervous System TumorsUnited States, Canada, Australia, Switzerland, New Zealand
-
Emory UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Abramson Cancer Center of the University of PennsylvaniaNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
Duke UniversityNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
St. Jude Children's Research HospitalCompletedBrain Tumors | Central Nervous System TumorsUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumors | Central Nervous System TumorsUnited States, Australia, Canada
-
Pediatric Brain Tumor ConsortiumNational Cancer Institute (NCI)CompletedVNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain TumorsBrain and Central Nervous System TumorsUnited States
-
University of Colorado, DenverNational Cancer Institute (NCI)CompletedBrain and Central Nervous System TumorsUnited States
-
National Cancer Institute (NCI)CompletedBrain and Central Nervous System Tumors
Clinical Trials on semaxanib
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedKidney CancerUnited States
-
National Cancer Institute (NCI)CompletedSarcoma | Gastrointestinal Stromal TumorUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Non-melanomatous Skin Cancer | Carcinoma of Unknown PrimaryUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)Completed
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)TerminatedColorectal CancerUnited States
-
Fox Chase Cancer CenterNational Cancer Institute (NCI)CompletedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
PfizerCompleted
-
National Cancer Institute (NCI)Completed